NCT06837155View on ClinicalTrials.gov

A QT/QTc Evaluation Study of TS-172 in Healthy Adult Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

March 3, 2025

Primary Completion Date

May 20, 2025

Study Completion Date

May 26, 2025

Conditions
Healthy Volunteers
Interventions
DRUG

TS-172 20 mg

oral administration of TS-172 20 mg

DRUG

TS-172 90 mg

oral administration of TS-172 90 mg

DRUG

Moxifloxacin

oral administration of moxifloxacin 400 mg

DRUG

Placebo

oral administration of placebo

Trial Locations (1)

Unknown

Taisho Pharmaceutical Co., Ltd selected site, Tokyo

All Listed Sponsors
lead

Taisho Pharmaceutical Co., Ltd.

INDUSTRY

NCT06837155 - A QT/QTc Evaluation Study of TS-172 in Healthy Adult Subjects | Biotech Hunter | Biotech Hunter